Eye Disease & Ophthalmology Clinical Trials Update: Week 27, 2026
Published July 3, 2026 — 5 trials covered
By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.
Fenofibrate for Prevention of DR Worsening
This Phase 3 trial by the Jaeb Center for Health Research is studying fenofibrate, a pill taken by mouth, to see if it can stop diabetic retinopathy from getting worse in adults with mild to moderate disease. If fenofibrate works, it could offer an easier and less invasive option to protect vision compared to current treatments that often require eye injections or laser therapy. The study is active but no longer recruiting, and results will come after following patients for a longer time.
A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy
Regeneron Pharmaceuticals is running this Phase 3 trial to test new antibody treatments for both adults and children with eye allergies caused by cat dander. These monoclonal antibodies aim to reduce redness, itching, and watering of the eyes with possibly fewer side effects than current allergy medicines. The study has not started enrolling people yet but plans to include 570 participants when it opens.
A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration
Outlook Therapeutics completed this Phase 3 trial testing ONS-5010, a new eye injection for wet age-related macular degeneration, a common cause of vision loss in older adults. The study involved 400 participants and looked at how safe and well the treatment works to slow or stop vision loss. Results from this study are now available, potentially offering another option for patients managing this condition.
A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration
This Phase 4 trial from Astellas Pharma is testing the safety of monthly ASP3021 eye injections over a year in adults aged 40 and older in Japan who have geographic atrophy caused by age-related macular degeneration. Geographic atrophy is a form of the disease that causes gradual vision loss without current effective treatments. If ASP3021 proves safe and helpful, it could slow vision loss for people living with this condition.
Smartphone Screening for Eye Diseases
The University of Michigan completed this study that tested a new way to screen for common eye diseases like diabetic retinopathy and glaucoma using a smartphone. This technology could make it easier to detect eye problems early, especially in communities that have less access to eye care. The study included 550 participants and results are expected soon, which may help improve early diagnosis and treatment.
TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.